These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Kulnigg-Dabsch S; Schmid W; Howaldt S; Stein J; Mickisch O; Waldhör T; Evstatiev R; Kamali H; Volf I; Gasche C Inflamm Bowel Dis; 2013 Jul; 19(8):1609-16. PubMed ID: 23644823 [TBL] [Abstract][Full Text] [Related]
3. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. Voudoukis E; Karmiris K; Oustamanolakis P; Theodoropoulou A; Sfiridaki A; Paspatis GA; Koutroubakis IE Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1212-6. PubMed ID: 23839158 [TBL] [Abstract][Full Text] [Related]
4. Thorax as an extraintestinal target for inflammatory bowel disease. Akpınar EE; Gülhan M; Değertekin H; Ataoğlu Ö Tuberk Toraks; 2011; 59(3):312-5. PubMed ID: 22087529 [No Abstract] [Full Text] [Related]
5. Role of 5-aminosalicylate in preventing colorectal cancer. Riyaz S; Hamlin J; Everett S Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414 [No Abstract] [Full Text] [Related]
6. An unusual case of extreme thrombocytosis caused by iron deficiency. Bergmann K; Bergmann OJ BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31919059 [TBL] [Abstract][Full Text] [Related]
7. [Current status of new drug development for inflammatory bowel diseases]. Kohgo Y; Tanabe H; Fujiya M Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121 [No Abstract] [Full Text] [Related]
8. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases]. Ioffe AIu Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Carty E; MacEy M; Rampton DS Aliment Pharmacol Ther; 2000 Sep; 14(9):1169-79. PubMed ID: 10971234 [TBL] [Abstract][Full Text] [Related]
10. Iron deficiency generates secondary thrombocytosis and platelet activation in inflammatory bowel disease : the randomized, controlled ThromboVIT trial. Zuo L; Li Y; Wang H; Zhu W Inflamm Bowel Dis; 2013 Oct; 19(11):E85. PubMed ID: 23962897 [No Abstract] [Full Text] [Related]
11. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. Spagnuolo R; Cosco C; Mancina RM; Ruggiero G; Garieri P; Cosco V; Doldo P Eur Rev Med Pharmacol Sci; 2017 Jun; 21(2 Suppl):102-107. PubMed ID: 28724171 [TBL] [Abstract][Full Text] [Related]
12. Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications. Collins CE; Rampton DS Aliment Pharmacol Ther; 1997 Apr; 11(2):237-47. PubMed ID: 9146760 [TBL] [Abstract][Full Text] [Related]
13. 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose. Qasim A; Seery J; O'Morain CA Dig Liver Dis; 2001; 33(5):393-8. PubMed ID: 11529648 [No Abstract] [Full Text] [Related]
14. [5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?]. Desreumaux P; Romano O Gastroenterol Clin Biol; 2004 May; 28(5):509. PubMed ID: 15243337 [No Abstract] [Full Text] [Related]
15. Mesenteric ischemia is a cause of resistance to treatment in IBD. Ibiş M; Ataseven H; Basar O; Yüksel I; Ulker A Inflamm Bowel Dis; 2009 Aug; 15(8):1129-30. PubMed ID: 18951366 [No Abstract] [Full Text] [Related]